Compare Norfolk Southern Corporation (NSC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Summit Therapeutics Inc — how do they compare? Norfolk Southern Corporation trades at $317.96 (market cap $71.20B), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: Norfolk Southern Corporation is far larger — about 5.2× Summit Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Summit Therapeutics Inc for 16 Days on average.
| NSC | SMMT | |
|---|---|---|
Market Cap | $71.20B | $13.71B |
Volume | 555,248 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $352.98 | $26.38 |
52-Week Low | $278.19 | $12.43 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $86.75B | $13.04B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $317.67, up 1.43% on the day, with a bullish technical signal supported by moving averages. The company has consistently beaten earnings estimates in recent quarters, with a strong net income margin of 21.02% (2026). Positive sentiment surrounds the proposed merger with Union Pacific, which is advancing through regulatory review and is backed by over 500 customers, as reported by Business Wire on September 22, 2026.
The outlook is positive, with a consensus price target of $361.86 offering ~14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures on margins and regulatory hurdles for the combination. Earnings on October 22, 2026, will be a critical catalyst.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
